BIT Capital’s Celldex Therapeutics CLDX Stock Holding History

BIT Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,313	Closed	-$171K	–	112
2023 Q4	$171K	Buy	+4,313	New	+$127K	0.02%	76

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BIT Capital's CLDX Position: Q1 2024 in Review

BIT Capital sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 4,313 shares — an estimated $171K sold.

BIT Capital first reported a position in CLDX in Q4 2023 and held it in 1 quarter. The position peaked at $171K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

BIT Capital reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
BIT Capital sold 4,313 Celldex Therapeutics shares in Q1 2024, an estimated $171K.
BIT Capital first reported a position in Celldex Therapeutics in Q4 2023 and held it in 1 quarter.
BIT Capital's Celldex Therapeutics position peaked at $171K in Q4 2023.
197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on BIT Capital's 13F filing for Q1 2024, filed 12 Feb 2025.